AB-2100

N/A

Report date: 2024/03/26 18:00:56

Base Information

Drug NameAB-2100
Drug Alias NameAB-2100
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArsenal Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesArsenal Biosciences Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A